Page 58 - GPD-4-2

Gene & Protein in Disease Orexin in depression

Bull. 2020;36(4):432-448. receptor-dependent pathway is implicated in the
doi: 10.1007/s12264-019-00447-9 development of overactive bladder and depression in rats
exposed to corticosterone. Neurourol Urodyn. 2024.
109. Esmaili-Shahzade-Ali-Akbari P, Ghaderi A, Sadeghi A,
Nejat F, Mehramiz A. The role of orexin receptor antagonists doi: 10.1002/nau.25602
in inhibiting drug addiction: A review article. Addict Health. 119. Kishi T, Koebis M, Sugawara M, Kawatsu Y, Taninaga T,
2024;16(2):130-139. Iwata N. Orexin receptor antagonists in the treatment of
doi: 10.34172/ahj.2024.1491 insomnia associated with psychiatric disorders: A systematic
review. Transl Psychiatry. 2024;14(1):374.
110. Alijanpour S, Khakpai F, Ebrahimi-Ghiri M, Zarrindast MR.
Co-administration of the low dose of orexin and nitrergic doi: 10.1038/s41398-024-03087-4
antagonists induces an antidepressant-like effect in mice. 120. Na HJ, Jeon N, Staatz CE, Han N, Baek IH. Clinical safety
Biomed Pharmacother. 2019;109:589-594. and narcolepsy-like symptoms of dual orexin receptor
doi: 10.1016/j.biopha.2018.10.033 antagonists in patients with Insomnia: A systematic review
and meta-analysis. Sleep. 2024;47(2):zsad293.
111. Kron JOJ, Keenan RJ, Hoyer D, Jacobson LH. Orexin receptor
antagonism: Normalizing sleep architecture in old age and doi: 10.1093/sleep/zsad293
disease. Annu Rev Pharmacol Toxicol. 2024;64:359-386. 121. Rocha RB, Bomtempo FF, Nager GB, Cenci GI, Telles
doi: 10.1146/annurev-pharmtox-040323-031929 JPM. Dual orexin receptor antagonists for the treatment of
Insomnia: Systematic review and network meta-analysis.
112. Brooks S, Jacobs GE, de Boer P, et al. The selective Arq Neuropsiquiatr. 2023;81(5):475-483.
orexin-2 receptor antagonist seltorexant improves sleep:
An exploratory double-blind, placebo controlled, crossover doi: 10.1055/s-0043-1768667
study in antidepressant-treated major depressive disorder 122. Zhou M, Tang J, Li S, Li Y, Zhao M. Orexin dual receptor
patients with persistent Insomnia. J Psychopharmacol. antagonists, zolpidem, zopiclone, eszopiclone, and cognitive
2019;33(2):202-209. research: A comprehensive dose-response meta-analysis.
doi: 10.1177/0269881118822258 Front Hum Neurosci. 2022;16:1029554.
113. Staton CD, Yaeger JDW, Khalid D, et al. Orexin 2 receptor doi: 10.3389/fnhum.2022.1029554
stimulation enhances resilience, while orexin 2 inhibition 123. Tsuneki H, Wada T, Sasaoka T. Chronopathophysiological
promotes susceptibility, to social stress, anxiety and
depression. Neuropharmacology. 2018;143:79-94. implications of orexin in sleep disturbances and lifestyle-
related disorders. Pharmacol Ther. 2018;186:25-44.
doi: 10.1016/j.neuropharm.2018.09.016
doi: 10.1016/j.pharmthera.2017.12.010
114. Jha MK. Selective orexin receptor antagonists as novel
augmentation treatments for major depressive disorder: 124. Berger B, Brooks S, Zuiker R, Richard M, Muehlan C,
Evidence for safety and efficacy from a phase 2B study of Dingemanse J. Pharmacological interactions between the
seltorexant. Int J Neuropsychopharmacol. 2022;25(1):85-88. dual orexin receptor antagonist daridorexant and ethanol
in a double-blind, randomized, placebo-controlled, double-
doi: 10.1093/ijnp/pyab078 dummy, four-way crossover phase I study in healthy
115. Recourt K, de Boer P, Zuiker R, et al. The selective orexin-2 subjects. CNS Drugs. 2020;34(12):1253-1266.
antagonist seltorexant (JNJ-42847922/MIN-202) shows doi: 10.1007/s40263-020-00768-8
antidepressant and sleep-promoting effects in patients with
major depressive disorder. Transl Psychiatry. 2019;9(1):216. 125. Xue T, Wu X, Li J, et al. Different doses of dual orexin
receptor antagonists in primary Insomnia: A Bayesian
doi: 10.1038/s41398-019-0553-z network analysis. Front Pharmacol. 2023;14:1175372.
116. Brotschi C, Bolli MH, Gatfield J, et al. Pyrazole derivatives as doi: 10.3389/fphar.2023.1175372
selective orexin-2 receptor antagonists (2-SORA): Synthesis,
structure-activity-relationship, and sleep-promoting 126. Krause A, Lott D, Brussee JM, Muehlan C, Dingemanse J.
properties in rats. RSC Med Chem. 2024;15(1):344-354. Population pharmacokinetic modeling of daridorexant, a
novel dual orexin receptor antagonist. CPT Pharmacometrics
doi: 10.1039/d3md00573a Syst Pharmacol. 2023;12(1):74-86.
117. Takaesu Y, Sakurai H, Aoki Y, et al. Treatment strategy doi: 10.1002/psp4.12877
for insomnia disorder: Japanese expert consensus. Front
Psychiatry. 2023;14:1168100. 127. Berger B, Kornberger R, Dingemanse J. Pharmacokinetic
and pharmacodynamic interactions between daridorexant,
doi: 10.3389/fpsyt.2023.1168100 a dual orexin receptor antagonist, and citalopram in healthy
118. Anna S, Jan W, Aleksandra S, et al. The orexin OX(2) subjects. Eur Neuropsychopharmacol. 2021;51:90-104.

Volume 4 Issue 2 (2025) 22 doi: 10.36922/gpd.4210